CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CORT is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business has strong growth catalysts and analyst sentiment is constructive, but the stock is already near resistance, insider selling is elevated, and the latest quarter showed weaker profitability even as revenue grew. My direct view: hold for now rather than buy immediately.
The trend is constructive but not ideal for an immediate entry. Price closed at 52.07, just above the pivot at 48.839 and essentially at first resistance R1 of 52.047, which suggests limited near-term upside from current levels. MACD histogram is positive at 0.356, though contracting, indicating momentum is still positive but losing strength. RSI_6 at 69.785 is near overbought territory, and moving averages are converging, which points to a flattening trend rather than a strong breakout. The stock trend model suggests positive short-term drift, but the current setup is more neutral-to-bullish than a clean buy signal.
Recent news is clearly favorable: Q1 2026 revenue rose to $164.9 million, the company raised 2026 revenue guidance to $950 million-$1.05 billion, Lifyorli was rapidly included in NCCN guidelines after FDA approval, and management sees major long-term expansion potential in both the Cushing's franchise and oncology. Analyst targets have been moving higher, including boosts to $75, $88, and $110, with multiple firms maintaining Buy/Overweight views. The early FDA approval for Lifyorli is a major event-driven catalyst.
The latest quarter showed net income and EPS falling sharply year over year despite revenue growth, which weakens near-term earnings quality. Insider trading data is negative, with insiders selling and the selling amount rising 271.06% over the last month. Technically, the stock is pressing into resistance and momentum is not accelerating. Also, hedge fund activity is neutral and there is no supportive congress trading signal.
In Q1 2026, Corcept reported revenue of $164.9 million, up 4.89% year over year, which confirms continued top-line growth. However, profitability weakened materially: net income fell to -$31.76 million and EPS dropped to -0.30. Gross margin remained very high at 98.25%, showing the core business still has strong product economics, but the quarter was not profitable. For a long-term investor, the revenue guidance raise is encouraging, but the latest quarter season was still mixed because growth was positive while earnings deteriorated.
Wall Street sentiment is bullish overall. H.C. Wainwright raised its target to $75 and reiterated Buy, Piper Sandler raised to $88 and kept Overweight, and Canaccord lifted its target to $110 with Buy after the early FDA approval of Lifyorli. Wolfe upgraded the stock to Peer Perform, citing the approval as removing a major downside scenario. The pros view is that the new oncology product and stronger guidance create upside, while the cautionary view is that the core Cushing's franchise still faces sustainability questions and prior generic-related pressure has reduced the bull case. Net takeaway: analysts are positive, but the stock already reflects meaningful optimism.
